Primary effusion lymphomas (PELs) are a rare type of nonHodgkin's lymphoma that are resistant to cytotoxic chemotherapy. PELs manifest constitutive activation of nuclear factor kappa B (NF-jB), and inhibition of NF-jB induces apoptosis of PELs and sensitizes to tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced death. Bortezomib (PS-341), a peptidyl boronic acid inhibitor of the proteasome, is a potent agent against a wide range of hematologic malignancies and has been shown to inhibit NF-jB. Thus, we examined the cytotoxic effects of bortezomib alone and in combination with various drugs. Bortezomib potently inhibited NF-jB in PEL cells in a dose-dependent manner. In addition, bortezomib inhibited growth and induced apoptosis of PEL cell lines (IC 50 values of 3.4-5.0 nM). Results of drug interactions between bortezomib and chemotherapy (doxorubicin and Taxol) were scheduledependent: synergistic interactions were generally observed when PEL cells were pretreated with bortezomib prior to chemotherapy, whereas additive or even antagonistic interactions occurred with chemotherapy pretreatment or simultaneous treatment with bortezomib and chemotherapy. Most schedules of bortezomib and dexamethasone were synergistic, although pretreatment with dexamethasone resulted in additive interactions. Effects of combinations of bortezomib and TRAIL were generally additive. Thus, bortezomib represents a promising potential therapy for the treatment of PEL.
Introduction
PELs, which occur in both human immunodeficiency viruspositive and -negative patients, represent a rare subtype of nonHodgkin's lymphoma that is uniformly infected with the Kaposi's sarcoma-associated herpesvirus, also known as human herpesvirus 8. Unlike most non-Hodgkin's lymphomas, PELs are relatively resistant to standard cytotoxic chemotherapy, and virtually all patients succumb to the disease with a median survival of approximately 60 days. 1 One of the biochemical hallmarks of PELs is constitutive NF-kB activation, which results in heightened expression of antiapoptotic genes and is critical for PEL cell survival. 2 In fact, drugs that inhibit NF-kB activation have exhibited considerable activity against PELs both in vitro and in vivo. [1] [2] [3] In addition, inhibition of NF-kB sensitizes PEL cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. 3 Recently, the proteasome inhibitor bortezomib (formerly PS-341) has demonstrated potent cytotoxicity across a wide variety of hematologic malignancies and solid tumors and received approval by the Food and Drug Administration (FDA) for the treatment of refractory multiple myeloma, where it has an acceptable toxicity profile. [4] [5] [6] By inhibiting the proteasome, which degrades proteins that are marked by ubiquitination, bortezomib modulates the cellular concentrations of hundreds of proteins that are involved in a wide variety of functions, including cell cycle progression, signal transduction, and apoptosis. 7, 8 For example, the proteasome regulates the activity of the NF-kB pathway, in that the degradation of I kappa B (IkB), the NF-kB inhibitory protein, is dependent upon the ubiquitinproteasome pathway. 9 Given the important role or heightened NF-kB activity in promoting the survival of PEL cells, 2 we postulated that bortezomib has potent cytotoxic effects on PELs. Thus, we studied the cytotoxic effects of bortezomib alone and in combination with TRAIL as well as chemotherapy and dexamethasone on PELs.
Materials and methods

Cells and reagents
The KS-1, BCBL-1, and BCP-1 PEL cell lines, which are infected with KSHV but not other herpesviruses, were maintained in RPMI plus 20% FBS and antibiotics. Bortezomib (Millennium Pharmaceuticals, Cambridge, MA, USA) and recombinant, human TRAIL (Calbiochem, San Diego CA, USA) were dissolved in dimethyl sulfoxide (DMSO) and phosphate-buffered saline (PBS), respectively. Bay 11-7082 (Calbiochem, San Diego, CA, USA), a chemical inhibitor of the NF-kB pathway, was dissolved in DMSO. Doxorubicin and paclitaxel (Taxol) were purchased from Sigma (St Louis, MO, USA) and dissolved in water and methanol, respectively. The corticosteroid, dexamethasone (Sigma) was dissolved in ethanol. For all experiments, the final concentration of solvents was maintained at 0.1%.
A kB responsive plasmid (p4x-kB-luc), in which four copies of the kB-response element (kB-RE) drives expression of firefly luciferase, was purchased from Invitrogen (Carlsbad, CA, USA). The pRL-SV40 plasmid, in which Renilla luciferase is constitutively expressed under the regulation of the SV40 promoter/ enhancer, was purchased from Promega Corporation (Madison, WI, USA) and was used for normalization of firefly luciferase activity.
Transient transfections and reporter gene assays
Cells were plated in 24-well plates the day prior to transfection. The plasmids were transfected with Lipofectamine Plus (Life Technologies, Gaithersburg, MD, USA), according to the manufacturer's instructions. Protein was extracted 48 h after transfection, and firefly and Renilla luciferase were measured on a TD20/20 tube luminometer (Turner Designs, Sunnyvale, CA, USA) using a Dual Luciferase Assay kit (Promega Corporation), according to the manufacturer's instructions. Firefly luciferase activity was normalized to Renilla luciferase expression.
Electrophoretic mobility shift assay (EMSA) and Western blotting
The EMSAs and Western blots were performed, as described. 10 
Assessment of cytotoxicity
Cells were seeded in 96-well plates the day prior to chemical treatment. Various drug combinations were added to cells, and 48 h later, cell viability was assessed by the MTT (3,[4,5-dimethylthiazol-2-yl-] diphenyltetrazolium bromide) assay. In total, 25 ml of MTT (5 mg/ml) was added to each well for 3 h at 371C. Subsequently, 120 ml of 10% sodium dodecyl sulfate/ 0.01 N HCl was added overnight at 371C. Absorbance was measured at 570 nm on a microplate reader. All experiments were performed in triplicate. 
Assessment of apoptosis
Median effect/combination index (CI) isobologram method for multiple drug effect analysis
The effect of drug combinations on cytotoxicity was performed by the median effect/combination index (CI) method using Calcusyn software, version 1.1.1 (Biosoft, Ferguson, MO, USA) as were the IC 50 values, as previously described. 11 CI and IC 50 values were calculated from median results of the MTT assays. Fixed drug ratios were maintained for CI analysis. CI values significantly greater than 1 indicate drug antagonism, CI values significantly less than 1 are indicative of synergy, and CI values not significantly different than 1 indicate an additive drug effect. Linear regression correlation coefficients of the median effects plots were required to be 40.90 to demonstrate that the effects of the drugs follow the law of mass action, which is required for a median effect analysis.
Results
Bortezomib inhibits constitutive NF-kB activation in PELs
Inhibition of NF-kB activity by bortezomib is considered to play a key role in its pro-apoptotic effects. 5, 12 Given the importance of NF-kB activation in the survival of B-cell malignancies including PELs, 1,2,13,14 we postulated that bortezomib would have potent apoptotic effects on PEL cells. As a prelude to study the cytotoxic effects of bortezomib, we tested the ability of bortezomib to block constitutive NF-kB activation in PELs. Bortezomib inhibited an NF-kB driven reporter in the BCBL-1 PEL cell lines in a dose-dependent manner ( Figure 1a ). The IC 50 for NF-kB inhibition was 2.8 nM. Similar results were obtained for the KS-1 and BCP-1 cell lines (data not shown). In addition, bortezomib blocked the nuclear localization of NF-kB transcription factors in BCBL-1 cells as demonstrated by EMSA (Figure 1b) . Previous studies have shown that the top and bottom NF-kB bands represent p65-p50 and p50-p50 dimers, respectively. 2 As further evidence of NF-kB inhibitory effects of bortezomib, we demonstrated that the drug blocked the degradation of IkBa (Figure 1c ), which is consistent with its function as a proteasome inhibitor.
The degree of NF-kB inhibition is less pronounced in the EMSA compared to the reporter assay because of the shorter duration of exposure to bortezomib (60 min) employed in the EMSA to avoid the nonspecific effects on intracellular protein levels and cellular health observed with proteasome inhibition. In contrast, the reporter assay ( Figure 1a ) allows for normalization for factors other than NF-kB transcriptional activity that may be affected by proteasome inhibition and, therefore, can be performed over a more prolonged duration.
Bortezomib potently inhibits growth and induces apoptosis of PELs
The cytotoxicity of bortezomib was measured on the BCP-1, BCBL-1, and KS-1 cell lines by the MTT assay. Bortezomib exhibited potent, dose-dependent cytotoxic effects on all cell lines after 48 h of drug exposure (Figure 2a) . The IC 50 values ranged from 3.4 to 5.0 nM. Annexin V staining of bortezomibtreated cells demonstrated that growth inhibition was predominantly due to apoptosis (Figure 2b ). In addition, the concentrations of bortezomib that inhibited NF-kB driven reporter gene expression correlated with those required to induce cytotoxicity and apoptosis (compare Figure 1a to Figure 2a, b) . For example, in BCBL-1 cells, the NF-kB inhibitory IC 50 was 2.8 nM and the IC 50 for growth was 4.4 nM. In an attempt to identify antiapoptotic proteins that may be affected by bortezomib treatment, we performed Western blots for NF-kB-regulated targets, cFLIP, XIAP, and BCL-XL. Interestingly, bortezomib did not affect the protein levels of any of these proteins (Supplementary Figure 1 ).
Drug interactions between bortezomib and chemotherapy/dexamethasone
The drug interactions between bortezomib and chemotherapy have been studied in other tumor models, and results have been variable. Whereas bortezomib and chemotherapy are synergistic in colon cancer, 15 they are additive in prostate cancer. 16 Using the BCBL-1, BCP-1 and KS-1 PEL cell lines, we studied the drug interactions between bortezomib and doxorubicin or Taxol (paclitaxel), two commonly used chemotherapeutic agents in the treatment of lymphomas. As single agents, doxorubicin and Taxol were minimally active in all three cell lines tested with IC 50 values that were in the B100-500 mM range (Supplementary Table 1 ). When we assessed the effects of drug combinations of bortezomib and either doxorubicin or Taxol by median effect/CI analysis, we found variable results depending upon drug scheduling. Thus, pretreatment with bortezomib for 24 h prior to exposure to either doxorubicin or Taxol generally resulted in synergistic drug interactions with CI values less than 1 across most concentrations tested (Figure 3 ). In contrast, pretreatment with chemotherapy for 24 h prior to bortezomib treatment or simultaneous exposure to both chemotherapy and bortezomib led to only additive or even antagonistic effects ( Figure 3) . When we tested different ratios of concentrations of bortezomib to chemotherapy other than the ratio used in Figure 3 (bortezomib:chemotherapy ¼ 1:10 000), the overall results of median effect/CI analysis remained the same (data not shown). Thus, the results of drug interactions between bortezomib and chemotherapy are schedule-dependent. We also tested the growth inhibitory effects of bortezomib in combination with the corticosteroid, dexamethasone. Similar to chemotherapy, dexamethasone had minimal effects as a single agent (data not shown). The combination of dexamethasone and bortezomib, when used simultaneously or with bortezomib pretreatment was synergistic for all three cell lines tested (Figure 4) . In contrast, dexamethasone pretreatment followed by bortezomib was generally additive, although the interaction was synergistic for BCBL-1 cells (Figure 4 ).
Drug interactions between bortezomib and TRAIL
Recent studies have demonstrated that interferon alpha (IFN-a) plus azidothymidine (AZT) results in marked apoptosis of PELs, 3, 4 which is mediated by IFN-a induction of high levels of TRAIL expression. 3, 17, 18 The pro-apoptotic effects of TRAIL, which ligates death receptors and thereby activates the extrinsic pathway of apoptosis, can be abrogated by its simultaneous activation of the antiapoptotic NF-kB pathway. 19, 20 Thus, it was further demonstrated that AZT sensitized to TRAIL by blocking NF-kB activation. Antitumor effects of bortezomib on PELs J An et al blocks NF-kB activation in PELs and TRAIL represents a potential cancer therapy that has been extensively studied in preclinical models, [21] [22] [23] [24] we studied the drug interactions between bortezomib and TRAIL.
Consistent with prior work, 17, 18 TRAIL had minimal cytotoxic effects on its own with approximately 10% reduction in PEL cell viability at 48 h at a concentration up to 200 ng/ml (data not shown). Unlike the synergistic interactions between IFN-a and TRAIL, when we treated PELs with bortezomib and TRAIL in combination, median effect/CI analysis demonstrated additive interactions across all concentrations and all schedules of both bortezomib and TRAIL (Supplementary Figure 2) . When we tested the drug interactions between Bay 11-7082, a specific inhibitor of the NF-kB pathway, and TRAIL, we found similar results as those obtained between bortezomib and TRAIL (Supplementary Figure 2) . Bay 11-7082 was active as a single agent, as previously reported (Supplementary Table 2) . 2 Thus, Bay 11-7082 and TRAIL combinations generally resulted in additive effects, which were schedule-independent.
Discussion
We have shown that bortezomib potently inhibits the growth and induces the apoptosis of PEL cells in vitro at pharmacologically achievable doses. The IC 50 values for bortezomib were in the low nanomolar range, which closely correspond to the IC 50 values for multiple myeloma, a disease for which bortezomib has shown significant clinical activity and has received FDA approval. 5, 6 In addition, bortezomib potently inhibits constitutive NF-kB activity. As selective inhibition of NF-kB can induce apoptosis of PELs 2 and our IC 50 values for growth and NF-kB Antitumor effects of bortezomib on PELs J An et al inhibition in PELs closely correlated, we postulate that inhibition of NF-kB plays a central role in the mechanism of bortezomibinduced death. When we evaluated the effects of bortezomib on the levels various antiapoptotic proteins (ie XIAP, cFLIP, BCL-XL), we observed no effect, indicating that bortezomib-induced growth inhibition functions through alternative mechanisms. Standard chemotherapy is ineffective in patients with PEL, and median life expectancy is approximately 2 months. 1 Our results confirm that the chemotherapeutic agents, doxorubicin and Taxol, are ineffective single agents against PEL cell lines in vitro. In addition, we rigorously studied the effects of drug interactions between bortezomib and doxorubicin or Taxol. In all three PEL cell lines tested, we observed synergistic interactions when cells were pretreated with bortezomib for 24 h prior to chemotherapy exposure. In contrast, pretreatment with chemotherapy or simultaneous exposure to bortezomib and chemotherapy resulted in additive or even antagonistic interactions. Thus, the results of drug interactions of bortezomib and chemotherapy are schedule-dependent. The mechanism that underlies the schedule dependence is unknown, but previous work in colon cancer has shown that resistance to topoisomerase II inhibitors, such as doxorubicin, may been overcome by proteasome inhibition prior to chemotherapy exposure and that this sensitization to chemotherapy by proteasome inhibition may be mediated by modulation of topoisomerase II protein levels. 25 Sensitization to Taxol by bortezomib has been demonstrated in pancreatic cancer and is mediated by inhibition of NF-kB activity, which is enhanced by Taxol exposure. 26 In PEL, we hypothesize that pretreatment with bortezomib may be required to downregulate NF-kB activity enough to overcome Taxol resistance.
Similar to the results with chemotherapy, interactions between dexamethasone and bortezomib were also scheduledependent, such that simultaneous exposure to both drugs or bortezomib pretreatment led to synergistic interactions. Initial treatment with dexamethasone was additive, except for one cell line, BCBL-1, for which this schedule resulted in synergy. Thus, synergistic interactions between dexamethasone and bortezomib were observed with more schedules as compared to the interactions between chemotherapy and bortezomib, for which synergy was only observed with pretreatment with chemotherapy prior to bortezomib exposure. Our drug interactions studies between bortezomib and TRAIL demonstrated additive effects.
These studies involved combinations of bortezomib and TRAIL that induced a wide range of cytotoxicity. Thus, we cannot attribute the lack of synergy to the use of concentrations of bortezomib that induced such high levels of cytotoxicity that they obscured a potential synergistic effect with TRAIL. These results contrast the synergistic interaction observed between AZT and TRAIL. 3 Interestingly, AZT sensitizes to TRAIL-induced apoptosis by blocking NF-kB activation. 3 Thus, although bortezomib and AZT effectively inhibit NF-kB, only AZT sensitizes PEL cells to TRAIL-induced death. This difference remains to be explained, although it may be attributed to effects of these drugs unrelated to NF-kB inhibition. In support of this concept, Bay 11-7082, a specific inhibitor of NF-kB activation, induces apoptosis of PELs, 2 yet AZT as a monotherapy does not, 3 suggesting that AZT may have heretofore undefined antiapoptotic effects that counterbalance its NF-kB inhibitory properties. In fact, when we tested drug interactions between Bay 11-7082 and TRAIL, very similar effects as those between bortezomib and TRAIL were observed, suggesting that inhibition of NF-kB represents a predominant mechanism of action of bortezomib.
Synergy between bortezomib and TRAIL has been observed in other tumor models, including murine kidney cancer and murine myeloid leukemia. In these murine models, bortezomib sensitized to TRAIL by reducing expression of cFLIP, an antiapoptotic protein that inhibits caspase 8 activation within the proximal portion of the extrinsic pathway of apoptosis. Interestingly, we found that bortezomib had no effect on cFLIP levels, which may account for the lack of synergy between bortezomib and TRAIL and indicates that the mechanism of action and downstream effects of bortezomib are apt to differ among various tumor models. 27 
Conclusion
This study is the first to report that bortezomib is an active agent against PELs. It is effective as a monotherapy as well as in schedule-dependent combination with chemotherapy and dexamethasone. As has recently been shown for patients with refractory, relapsed multiple myeloma, bortezomib can be used safely in patients and results in an acceptable toxicity profile. 6 Thus, bortezomib represents a promising agent for PELs, a Median effect/CI analysis of dexamethasone (DEX) and bortezomib. PEL cells were plated and treated, and the results were analyzed in a similar manner as described in Figure 3 . PEL cells were either pretreated with bortezomib for 24 h prior to an additional 24 h of DEX exposure or vice versa or cells were simultaneously treated with both drugs for 48 h. The ratio of bortezomib (nM):DEX (mM) was held at 1:5.
disease for which standard cytotoxic chemotherapy has proven to be ineffective.
